FREMONT, Calif. , Feb. 17, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab , president and chief executive officer of Ardelyx, will participate in a fireside chat at the 10 th Annual SVB Leerink Global Healthcare Conference at 3:00 p.m. ET on Wednesday , Feb. 24, 2021.
To access the webcast of Ardelyx's presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations . A replay of the fireside chat will be available on the Ardelyx website for 60 days following the presentation.
About Ardelyx, Inc.
Ardelyx is focused on developing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiovascular diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA, with a PDUFA date of April 29, 2021 . Ardelyx is also advancing RDX013, a potassium secretagogue program, for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELA ® (tenapanor) on September 12, 2019 . Ardelyx has established agreements with Kyowa Kirin in Japan , Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories.
View original content to download multimedia: http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-301229549.html
SOURCE Ardelyx
